Portal de investigação
Long-term consequences of osteoporosis therapy with bisphosphonates
Data de publicação:
Autores da FMUP
Participantes de fora da FMUP
- Gehrke, Barbara
- d'Alva, Catarina Brasil
- Madeira, Miguel
Unidades de investigação
Abstract
Bisphosphonates (BPs) are medications widely used in clinical practice to treat osteoporosis and reduce fragility fractures. Its beneficial effects on bone tissue have been consolidated in the literature for the last decades. They have a high affinity for bone hydroxyapatite crystals, and most bisphosphonates remain on the bone surface for a long period of time. Benefits of long-term use of BPs: Large and important trials (Fracture Intervention Trial Long-term Extension and Health Outcomes and Reduced Incidence with Zoledronic acid Once Yearly-Pivotal Fracture Trial) with extended use of alendronate (up to 10 years) and zoledronate (up to 6 years) evidenced significant gain of bone mineral density (BMD) and vertebral fracture risk reduction. Risks of long-term use of BPs: The extended use of antiresorptive therapy has drawn attention to two extremely rare, although severe, adverse events. That is, atypical femoral fracture and medication-related osteonecrosis of the jaw are more common in patients with high cumulative doses and longer duration of therapy. BPs have demonstrated safety and effectiveness throughout the years and evidenced increased BMD and reduced fracture risks, resulting in reduced morbimortality, and improved quality of life. These benefits overweight the risks of rare adverse events.
Dados da publicação
- ISSN/ISSNe:
- 2359-3997, 2359-4292
- Tipo:
- Review
- Páginas:
- 1-8
- PubMed:
- 37948565
ARCHIVES OF ENDOCRINOLOGY METABOLISM Segmento Farma Editores
Citações Recebidas na Web of Science: 41
Citações Recebidas na Scopus: 44
Documentos
- Não há documentos
Filiações
Keywords
- Bisphosphonate; osteoporosis; fracture; osteonecrosis of the jaw; atypical femoral fracture
Projetos associados
Mind the gap: An insight into the temporal relationship between initiation of cannabis use and onset of psychosis
Investigador Principal: Maria Augusta Vieira Coelho
Estudo Clínico Académico . 2022
Plasma levels of oleoylethanolamide in patients with feeding and eating disorders
Investigador Principal: Maria Augusta Vieira Coelho
Estudo Clínico Académico . 2022
Perceção do risco associado ao uso de drogas em doentes com história prévia de psicose induzida por cannabis
Investigador Principal: Maria Augusta Vieira Coelho
Estudo Clínico Académico . 2022
Ongoing Clinical Trials with Monoclonal Antibodies in Schizophrenia
Investigador Principal: Maria Augusta Vieira Coelho
Estudo Clínico Académico . 2020
Impulsivity and Its Relationship With Lisdexamfetamine Dimesylate Treatment in Binge Eating Disorder
Investigador Principal: Maria Augusta Vieira Coelho
Ensaio Clínico Académico (Eating Disorder) . 2022
Effect of the COVID-19 pandemic in patients with Obsessive-Compulsive Disorder
Investigador Principal: Maria Augusta Vieira Coelho
Estudo Clínico Académico . 2022
The role of opicapone for the treatment of patients with Parkinson´s Disease: clinical evidence
Investigador Principal: Maria Augusta Vieira Coelho
Estudo Clínico Académico . 2023
O Sistema Endocanabinoide na Patofisiologia da Fibrose Dérmica
Investigador Principal: Maria Augusta Vieira Coelho
Estudo Clínico Académico . 2021
Citar a publicação
Gehrke B,Coelho MCA,d'Alva CB,Madeira M. Long-term consequences of osteoporosis therapy with bisphosphonates. Arch. Endocrinol. Metab. 2024. 68(1):p. 1-8. IF:1,700. (4).
